A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Ord, Rosalynn L ^a   Caldeira, Jerri C ^b   Rodriguez, Marilis ^a   Noe, Amy ^c   Chackerian, Bryce ^b   Peabody, David S ^b   Gutierrez, Gabriel ^c   Lobo, Cheryl A ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; EPITOPE; MALARIA VACCINE; MONOCLONAL ANTIBODY; PEPTIDE; PLASMODIUM FALCIPARUM RH5 PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; NEUTRALIZING ANTIBODY; PROTOZOON ANTIBODY; RH5 PROTEIN, PLASMODIUM FALCIPARUM;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELL INVASION; CONTROLLED STUDY; DRUG POTENCY; ERYTHROCYTE; GROWTH INHIBITION; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; MS2 VIRUS; NONHUMAN; PEPTIDE LIBRARY; PLASMODIUM FALCIPARUM; VACCINATION; VIRUS LIKE AGENT; ANIMAL; EPITOPE MAPPING; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, PROTOZOAN; CARRIER PROTEINS; EPITOPE MAPPING; EPITOPES; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; NEUTRALIZATION TESTS; PLASMODIUM FALCIPARUM;

EID: 84906933352     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-326     Document Type: Article

References (40)

1. The pathogenic basis of malaria. Miller LH, Baruch DI, Marsh K, Doumbo OK, Nature 2002 415 673 679 10.1038/415673a 11832955
2. Falciparum malaria parasites invade erythrocytes that lack glycophorin A and B (MkMk). Strain differences indicate receptor heterogeneity and two pathways for invasion. Hadley TJ, Klotz FW, Pasvol G, Haynes JD, McGinniss MH, Okubo Y, Miller LH, J Clin Invest 1987 80 1190 1193 10.1172/JCI113178 3308959
3. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Camus D, Hadley TJ, Science 1985 230 553 556 10.1126/science.3901257 3901257
4. Glycophorin B as an EBA-175 independent Plasmodium falciparum receptor of human erythrocytes. Dolan SA, Proctor JL, Alling DW, Okubo Y, Wellems TE, Miller LH, Mol Biochem Parasitol 1994 64 55 63 10.1016/0166-6851(94)90134-1 8078523
5. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Sim BK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH, Science 1994 264 1941 1944 10.1126/science.8009226 8009226
6. EBL-1, a putative erythrocyte binding protein of Plasmodium falciparum, maps within a favored linkage group in two genetic crosses. Peterson DS, Wellems TE, Mol Biochem Parasitol 2000 105 105 113 10.1016/S0166-6851(99)00173-5 10613703
7. An expanding ebl family of Plasmodium falciparum. Adams JH, Blair PL, Kaneko O, Peterson DS, Trends Parasitol 2001 17 297 299 10.1016/S1471-4922(01)01948-1 11378038
8. Polymorphism in the Plasmodium falciparum erythrocyte-binding ligand JESEBL/EBA-181 alters its receptor specificity. Mayer DC, Mu JB, Kaneko O, Duan J, Su XZ, Miller LH, Proc Natl Acad Sci U S A 2004 101 2518 2523 10.1073/pnas.0307318101 14983041
9. Recombinant Plasmodium falciparum reticulocyte homology protein 4 binds to erythrocytes and blocks invasion. Gaur D, Singh S, Singh S, Jiang L, Diouf A, Miller LH, Proc Natl Acad Sci U S A 2007 104 17789 17794 10.1073/pnas.0708772104 17971435
10. Reticulocyte-binding protein homologue 1 is required for sialic acid-dependent invasion into human erythrocytes by Plasmodium falciparum. Triglia T, Duraisingh MT, Good RT, Cowman AF, Mol Microbiol 2005 55 162 174 15612925
11. Erythrocyte-binding antigen 175 mediates invasion in Plasmodium falciparum utilizing sialic acid-dependent and -independent pathways. Duraisingh MT, Maier AG, Triglia T, Cowman AF, Proc Natl Acad Sci U S A 2003 100 4796 4801 10.1073/pnas.0730883100 12672957
12. Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Hayton K, Gaur D, Liu A, Takahashi J, Henschen B, Singh S, Lambert L, Furuya T, Bouttenot R, Doll M, Nawaz F, Mu J, Jiang L, Miller LH, Wellems TE, Cell Host Microbe 2008 4 40 51 10.1016/j.chom.2008.06.001 18621009
13. PfRH5: a novel reticulocyte-binding family homolog of Plasmodium falciparum that binds to the erythrocyte, and an investigation of its receptor. Rodriguez M, Lustigman S, Montero E, Oksov Y, Lobo CA, PLoS One 2008 3 3300 10.1371/journal.pone.0003300 18827878
14. Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand. Tham WH, Wilson DW, Lopaticki S, Schmidt CQ, Tetteh-Quarcoo PB, Barlow PN, Richard D, Corbin JE, Beeson JG, Cowman AF, Proc Natl Acad Sci U S A 2010 107 17327 17332 10.1073/pnas.1008151107 20855594
15. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, Uchikawa M, Mboup S, Ndir O, Kwiatkowski DP, Duraisingh MT, Rayner JC, Wright GJ, Nature 2011 480 534 537 22080952
16. Invasion of red blood cells by malaria parasites. Cowman AF, Crabb BS, Cell 2006 124 755 766 10.1016/j.cell.2006.02.006 16497586
17. Reticulocyte-binding protein homologue 5-an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Baum J, Chen L, Healer J, Lopaticki S, Boyle M, Triglia T, Ehlgen F, Ralph SA, Beeson JG, Cowman AF, Int J Parasitol 2009 39 371 380 10.1016/j.ijpara.2008.10.006 19000690
18. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Bustamante LY, Bartholdson SJ, Crosnier C, Campos MG, Wanaguru M, Nguon C, Kwiatkowski DP, Wright GJ, Rayner JC, Vaccine 2013 31 373 379 10.1016/j.vaccine.2012.10.106 23146673
19. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL, Wyllie DH, Crosnier C, Miura K, Wright GJ, Long CA, Osier FH, Marsh K, Turner AV, Hill AV, Draper SJ, Nat Commun 2011 2 601 22186897
20. Targeting sialic acid dependent and independent pathways of invasion in Plasmodium falciparum. Ord RL, Rodriguez M, Yamasaki T, Takeo S, Tsuboi T, Lobo CA, PLoS One 2012 7 30251 10.1371/journal.pone.0030251 22253925
21. Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies. Reddy KS, Pandey AK, Singh H, Sahar T, Emmanuel A, Chitnis CE, Chauhan VS, Gaur D, Infect Immun 2014 82 152 164 10.1128/IAI.00970-13 24126527
22. Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. Patel SD, Ahouidi AD, Bei AK, Dieye TN, Mboup S, Harrison SC, Duraisingh MT, J Infect Dis 2013 208 1679 1687 10.1093/infdis/jit385 23904294
23. Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. Tran TM, Ongoiba A, Coursen J, Crosnier C, Diouf A, Huang CY, Li S, Doumbo S, Doumtabe D, Kone Y, Bathily A, Dia S, Niangaly M, Dara C, Sangala J, Miller LH, Doumbo OK, Kayentao K, Long CA, Miura K, Wright GJ, Traore B, Crompton PD, J Infect Dis 2014 209 789 798 10.1093/infdis/jit553 24133188
24. Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. Douglas AD, Williams AR, Knuepfer E, Illingworth JJ, Furze JM, Crosnier C, Choudhary P, Bustamante LY, Zakutansky SE, Awuah DK, Alanine DG, Theron M, Worth A, Shimkets R, Rayner JC, Holder AA, Wright GJ, Draper SJ, J Immunol 2014 192 245 258 10.4049/jimmunol.1302045 24293631
25. Characterization of PfRhop148, a novel rhoptry protein of Plasmodium falciparum. Lobo CA, Rodriguez M, Hou G, Perkins M, Oskov Y, Lustigman S, Mol Biochem Parasitol 2003 128 59 65 10.1016/S0166-6851(03)00050-1 12706797
26. Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles. Chackerian B, Caldeira Jdo C, Peabody J, Peabody DS, J Mol Biol 2011 409 225 237 10.1016/j.jmb.2011.03.072 21501621
27. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, do Carmo Caldeira J, Chackerian B, J Mol Biol 2008 380 252 263 10.1016/j.jmb.2008.04.049 18508079
28. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Caldeira Jdo C, Medford A, Kines RC, Lino CA, Schiller JT, Chackerian B, Peabody DS, Vaccine 2010 28 4384 4393 10.1016/j.vaccine.2010.04.049 20434554
29. Subunit fusion confers tolerance to peptide insertions in a virus coat protein. Peabody DS, Arch Biochem Biophys 1997 347 85 92 10.1006/abbi.1997.0312 9344468
30. Various PfRH5 polymorphisms can support Plasmodium falciparum invasion into the erythrocytes of owl monkeys and rats. Hayton K, Dumoulin P, Henschen B, Liu A, Papakrivos J, Wellems TE, Mol Biochem Parasitol 2013 187 103 110 10.1016/j.molbiopara.2012.12.005 23305874
31. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Amanna IJ, Slifka MK, Immunol Rev 2010 236 125 138 10.1111/j.1600-065X.2010.00912.x 20636813
32. Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. Paus D, Phan TG, Chan TD, Gardam S, Basten A, Brink R, J Exp Med 2006 203 1081 1091 10.1084/jem.20060087 16606676
33. The tipping points in the initiation of B cell signalling: how small changes make big differences. Pierce SK, Liu W, Nat Rev Immunol 2010 10 767 777 10.1038/nri2853 20935671
34. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA, Cancer Prev Res (Phila) 2013 6 1242 1250 10.1158/1940-6207.CAPR-13-0203 24189371
35. Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. Williams AR, Douglas AD, Miura K, Illingworth JJ, Choudhary P, Murungi LM, Furze JM, Diouf A, Miotto O, Crosnier C, Wright GJ, Kwiatkowski DP, Fairhurst RM, Long CA, Draper SJ, PLoS Pathog 2012 8 1002991 10.1371/journal.ppat.1002991 23144611
36. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Vardas E, Aranda C, Jessen H, Ferris DG, Coutlee F, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EI, Clin Vaccine Immunol 2012 19 261 267 10.1128/CVI.05208-11 22155768
37. Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. Lopez-Macias C, Hum Vaccin Immunother 2012 8 411 414 10.4161/hv.18757 22330956
38. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Wang JW, Roden RB, Expert Rev Vaccines 2013 12 129 141 10.1586/erv.12.151 23414405
39. Hepatitis E vaccine development: a 14 year odyssey. Wu T, Li SW, Zhang J, Ng MH, Xia NS, Zhao Q, Hum Vaccin Immunother 2012 8 823 827 10.4161/hv.20042 22699438
40. A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Tumban E, Peabody J, Peabody DS, Chackerian B, Vaccine 2013 31 4647 4654 10.1016/j.vaccine.2013.07.052 23933337